Lind Global reports 4.96% stake in Silexion

Silexion Therapeutics Corp Schedule 13G/A amendment: Lind Global-related entities report beneficial ownership of 212,500 securities, representing 4.96% of the class.

Rhea-AI Filing Summary

Silexion Therapeutics Corp Schedule 13G/A amendment: Lind Global-related entities report beneficial ownership of 212,500 securities, representing 4.96% of the class. The holdings consist of 106,250 Series A-1 Warrants and 106,250 Series A-2 Warrants, each subject to an exercise limitation that prevents exercise if such exercise would raise beneficial ownership above 9.9%. The filing lists Lind Global Fund III LP, Lind Global Partners III LLC and Jeff Easton as reporting persons and shows sole voting and dispositive power for 212,500 instruments.

Insights

Securities Compliance Analyst

13G/A discloses sub-5% warrant position with a 9.9% exercise cap.

The amendment reports 212,500 warrants held by Lind Global Fund III LP and related reporting persons, shown as 4.96% of the class. The filing specifies sole voting and dispositive power for the reported amount.

The warrants are split into 106,250 Series A-1 and 106,250 Series A-2 instruments and include a contractual limitation preventing exercise that would push ownership above 9.9%. Subsequent disclosures may clarify timing or conversion mechanics if exercised.

Equity Capital Markets Specialist

Position is a nondispositive passive holding below 5% threshold but expressed via warrants.

The filing is an ownership disclosure under Schedule 13G/A that classifies the position at 4.96%. The holdings are warrants rather than currently outstanding common shares, and exercise is conditionally capped.

Cash-flow treatment and conversion timing are not detailed in the excerpt; any market impact depends on whether and when warrants convert into ordinary shares subject to the 9.9% cap.

Key Figures

Beneficial ownership: 212,500 shares Percent of class: 4.96% Series A-1 Warrants: 106,250 warrants +2 more

5 metrics

Beneficial ownership 212,500 shares reported amount on cover rows

Percent of class 4.96% percent of class reported on cover rows

Series A-1 Warrants 106,250 warrants part of reporting person's ownership

Series A-2 Warrants 106,250 warrants part of reporting person's ownership

Exercise ownership cap 9.9% warrants may not be exercised above this beneficial ownership threshold

Key Terms

Series A-1 Warrants, Series A-2 Warrants, Beneficial ownership, Sole dispositive power

4 terms

Series A-1 Warrants financial

"The reporting person's ownership consists of (i) 106,250 warrants to purchase ordinary shares (the "Series A-1 Warrants")"

Series A-1 warrants are tradable instruments that give their holder the right, but not the obligation, to buy a company’s shares at a preset price for a limited time; they are typically issued alongside a specific financing round labeled “Series A-1.” Think of them like a coupon that lets an investor buy stock at a locked-in price later — if the company’s share price rises above that price the coupon becomes valuable, otherwise it may expire worthless. For investors they matter because exercising warrants can increase potential upside while also diluting existing shareholders and affecting future ownership percentages and share value.

Series A-2 Warrants financial

"and (ii) 106,250 warrants to purchase ordinary shares (the "Series A-2 Warrants")"

Series A-2 warrants are a specific class of long‑term options issued by a company that give the holder the right to buy a set number of shares at a pre‑agreed price. Think of them as a coupon for future stock purchases: they can add potential value for the holder if the share price rises, but they also represent potential dilution for existing shareholders and can affect an investor’s ownership and returns when exercised or converted.

Beneficial ownership regulatory

"Such Warrants may not be exercised if, following such exercise, the reporting person's beneficial ownership would exceed 9.9%"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Sole dispositive power regulatory

"Sole Dispositive Power 212,500.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Lind Global report in Silexion (SLXN)?

Lind Global-related reporting persons disclose beneficial ownership of 212,500 instruments, equal to 4.96% of the class. The filing lists sole voting and dispositive power for the 212,500 securities.

What instruments comprise the 212,500 holdings?

The position consists of 106,250 Series A-1 Warrants and 106,250 Series A-2 Warrants. The filing describes the holdings specifically as those two warrant series.

Are there limits on exercising the warrants?

Yes. The warrants "may not be exercised if, following such exercise, the reporting person's beneficial ownership would exceed 9.9%." This contractual cap is stated in the filing.

Who are the reporting persons on the Schedule 13G/A?

The statement is filed by Lind Global Fund III LP, Lind Global Partners III LLC (general partner), and Jeff Easton as managing member. The filing lists a New York business address for the reporting persons.

Does the filing show share voting or disposition powers?

Yes. For each reporting person the cover rows show sole voting power: 212,500 and sole dispositive power: 212,500, matching the reported beneficial amount.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 04:13 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Silexion Therapeutics Corp

(Name of Issuer)

Ordinary shares, par value $0.0135 per share

(Title of Class of Securities)

G1281K122

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): G1281K122

1

Names of Reporting Persons

Lind Global Fund III LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 212,500.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 212,500.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

212,500.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.96 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: (1) The reporting person's ownership consists of (i) 106,250 warrants to purchase ordinary shares (the "Series A-1 Warrants") and (ii) 106,250 warrants to purchase ordinary shares (the "Series A-2 Warrants, together with the Series A-1 Warrants, the "Warrants"). Such Warrants may not be exercised if, following such exercise, the reporting person's beneficial ownership would exceed 9.9%.

SCHEDULE 13G

CUSIP Number(s): G1281K122

1

Names of Reporting Persons

Lind Global Partners III LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 212,500.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 212,500.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

212,500.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.96 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: (1) The reporting person's ownership consists of (i) 106,250 Series A-1 Warrants and (ii) 106,250 Series A-2 Warrants. Such Warrants may not be exercised if, following such exercise, the reporting person's beneficial ownership would exceed 9.9%.

SCHEDULE 13G

CUSIP Number(s): G1281K122

1

Names of Reporting Persons

EASTON JEFF

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 212,500.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 212,500.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

212,500.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.96 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: (1) The reporting person's ownership consists of (i) 106,250 Series A-1 Warrants and (ii) 106,250 Series A-2 Warrants. Such Warrants may not be exercised if, following such exercise, the reporting person's beneficial ownership would exceed 9.9%.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Silexion Therapeutics Corp
(b)	Address of issuer's principal executive offices: 12 Abba Hillel Road, Ramat-Gan, Israel, 5250606
Item 2.
(a)	Name of person filing: This statement is filed by the following entities and individuals (collectively, referred to as the "Reporting Persons"): Lind Global Fund III LP, a Delaware limited partnership; Lind Global Partners III LLC, a Delaware limited liability company; and Jeff Easton, an individual and a citizen of the United States of America. Lind Global Partners III LLC, the general partner of Lind Global Fund III LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund III LP. Jeff Easton, the managing member of Lind Global Partners III LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund III LP.
(b)	Address or principal business office or, if none, residence: The address of the principal business office for each of the Reporting Persons is: 444 Madison Ave, Floor 41 New York, NY 10022
(c)	Citizenship: See Row 4 of cover page for each Reporting Person.
(d)	Title of class of securities: Ordinary shares, par value $0.0135 per share
(e)	CUSIP No.: G1281K122
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Row 9 of cover page for each Reporting Person.
(b)	Percent of class: See Row 11 of cover page for each Reporting Person.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.
	(ii) Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.
	(iii) Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.
	(iv) Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Lind Global Fund III LP

Signature:	By: Lind Global Partners III LLC, its General Partner, By: /s/ Jeff Easton
Name/Title:	Jeff Easton, Managing Member
Date:	05/15/2026

Lind Global Partners III LLC

Signature:	By: Lind Global Partners III LLC, its General Partner, By: /s/ Jeff Easton
Name/Title:	Jeff Easton, Managing Member
Date:	05/15/2026

EASTON JEFF

Signature:	/s/ Jeff Easton
Name/Title:	Jeff Easton
Date:	05/15/2026